Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRECO: Benralizumab Auto-Injector Functionality in Severe Asthma
NCT02918071Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in severe asthma, sponsored by AstraZeneca. Primary endpoints: Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home at Week 16, Number of Returned AI Devices Used to Administer Benralizumab at Home That Have Been Evaluated as Functional at Week 16 and 1 more. Started Nov 2016; status: completed.
02
Drugs
benralizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT02918071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918071.